BRCA2 and neoplasm: In fact, in preclinical models, mutations in Brca1 and Brca2 have been shown to influence response to immune checkpoint inhibitors (ICIs), with anti-PD-l blockade only improving survival of mice harbouring Brca1-null tumours [19].